Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Durvalumab After Trimodality Therapy in Muscle-Invasive Bladder Cancer
NCT03768570Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Oct 2019
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of durvalumab in muscle-invasive bladder cancer (MIBC), sponsored by Canadian Cancer Trials Group. Started Oct 2019; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT03768570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768570.